The Ministry of Health is considering the following drugs for PharmaCare coverage:

The Ministry of Health is considering the following drugs for PharmaCare coverage:

Generic name: bulevirtide

Brand name: Hepcludex®

Drug used for: The treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.

Tentative Dates for Input: From Wednesday, July 30, 2025, to Tuesday, August 26, 2025

AT 11:59 PM

Generic name: pegunigalsidase alfa

Brand name: TBC (to be confirmed)

Drug used for: Long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).

Tentative Dates for Input: From Wednesday, July 30, 2025, to Tuesday, August 26, 2025

AT 11:59 PM

Generic name: risankizumab

Brand name: Skyrizi®

Drug used for: The treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy or advanced therapy.

Tentative Dates for Input: From Wednesday, July 30, 2025, to Tuesday, August 26, 2025

AT 11:59 PM

Generic name: risperidone long-acting injection

Brand name: Okedi®

Drug used for: The treatment of schizophrenia in adults.

Tentative Dates for Input: From Wednesday, July 30, 2025, to Tuesday, August 26, 2025

AT 11:59 PM

Generic name: Lemborexant

Brand name: Dayvigo®

Drug used for: The treatment of insomnia in adults diagnosed according to the most recent version of the Diagnostic and Statistical Manual of Mental Disorders (DSM) referring to chronic insomnia disorder (CID).

Tentative Dates for Input: From Wednesday, July 30, 2025, to Tuesday, August 26, 2025

AT 11:59 PM

To provide input, please visit our website at http://www.gov.bc.ca/bcyourvoice.

IMPORTANT: The Ministry of Health must receive input for the drugs listed above no later than 11:59 PM on Tuesday, August 26, 2025.